Countries / Uganda
UG · NDA
Uganda
- Authority
- National Drug Authority (NDA)
- Legal basis
- Not recorded
- Address
- Not recorded
- Website
- https://www.nda.or.ug
- Notice channel
- https://www.nda.or.ug/circulars-2/Circulars are Uganda's real channel. The legacy recalls page has been dead since 2018.
- Coverage
- Partial
- Cadence
- Daily
- On the register
- 12 recorded actions
- Last verified
- 19 August 2026
Authority Channel
A named officer of NDA can put a Uganda alert on the register directly, with no review step of ours. Those records carry Tier 0 — entered and published by the issuing regulator, which is the one rank we cannot create for ourselves.
Nothing on this page carries Tier 0 today because no NDA officer holds a credential yet. We issue one after confirming, out of band, that a person speaks for their authority — write to notices@drugeyeafrica.org. Notices can also be sent by email, by export, or from an existing system: how to send them.
What we monitor, and what we cannot. PDF-only publication; requires OCR before dates and batches exist. Cadence: Daily. Last checked 19 August 2026.
| Reference | Date | Country | Product | Batches | Action | Class | Source |
|---|---|---|---|---|---|---|---|
| DEA-UG-2026-18763434 | 03 Mar 2026 | UG | Unauthorized sale of public family planning commodities in the private sector | none published | Public warning | Unclassified | Tier 1 · Regulator-published |
| DEA-UG-2025-48246675 | 04 Dec 2025 | UG | Paracetamol-containing oral solid dosage forms | none published | Scheduling change | Unclassified | Tier 1 · Regulator-published |
| DEA-UG-2024-49858519 | 11 Sept 2024 | UG | Circular on Unaunthorised Medical Devices on the Ugandan Market | none published | Public warning | Unclassified | Tier 1 · Regulator-published |
| DEA-UG-2024-54413197 | 20 Feb 2024 | UG | Ketoconazole oral tablets | none published | Deregistration | Unclassified | Tier 1 · Regulator-published |
| DEA-UG-2023-17500876 | 18 Aug 2023 | UG | Adulterated L-power coffee supplied by Liven Global SDN. BHD – Malaysia | none published | Public warning | Unclassified | Tier 1 · Regulator-published |
| DEA-UG-2022-85899679 | 13 Oct 2022 | UG | Unauthorized Chinese Pill Tablets on the Market | none published | Public warning | Unclassified | Tier 1 · Regulator-published |
| DEA-UG-2022-27953969 | 10 Oct 2022 | UG | WHO Global alert on substandard (contaminated) pediatric cough syrups identified in Gambia – West Africa | none published | Public warning | Unclassified | Tier 1 · Regulator-published |
| DEA-UG-2022-47522751 | 25 Jul 2022 | UG | Ban on the use Chloroform (Trichloromethane) in Pharmaceutical preparations | none published | Ban | Unclassified | Tier 1 · Regulator-published |
| DEA-UG-2019-36916109 | 31 Oct 2019 | UG | Ranitidine | none published | Import hold | Unclassified | Tier 1 · Regulator-published |
| DEA-UG-2019-26477586 | 01 Mar 2019 | UG | Adulterated Herbal products on the market | none published | Public warning | Unclassified | Tier 1 · Regulator-published |
| DEA-UG-2019-52040565 | 22 Jan 2019 | UG | Furosemide Injection BP Grand Pharmaceutical (China) Co., Ltd. | 180120 | Recall | Unclassified | Tier 1 · Regulator-published |
| DEA-UG-2018-40370607 | 22 Mar 2018 | UG | Rabicid-IV (Rabeprazole Injection IP) | none published | Public warning | Unclassified | Tier 1 · Regulator-published |
| Reference | Date | Country | Notice | Batches | Action | Class | Source |
|---|---|---|---|---|---|---|---|
| DEA-UG-2025-31556372 | 02 Jul 2025 | UG | Retention of products on the register for the financial year 2025/2026 | none published | Guidance | Unclassified | Tier 1 · Regulator-published |
| DEA-UG-2025-45726480 | 08 May 2025 | UG | Regulation of promotion and advertisement of drug related information | none published | Guidance | Unclassified | Tier 1 · Regulator-published |
| DEA-UG-2025-39573016 | 18 Mar 2025 | UG | Clarification on fees payable for post approval amendments (variations) applications affecting multiple products | none published | Guidance | Unclassified | Tier 1 · Regulator-published |
| DEA-UG-2024-76423948 | 07 Oct 2024 | UG | Mandatory Post Shipment Circular | none published | Guidance | Unclassified | Tier 1 · Regulator-published |
| DEA-UG-2024-32874724 | 09 Sept 2024 | UG | Fast-Track assessment of variations (Amendments) and CTD dossier applications | none published | Guidance | Unclassified | Tier 1 · Regulator-published |
| DEA-UG-2024-14554633 | 13 Mar 2024 | UG | Circular on Importation of Healthcare Products for surgical / medical/ dental camps | none published | Guidance | Unclassified | Tier 1 · Regulator-published |
| DEA-UG-2024-93633050 | 08 Feb 2024 | UG | Circular No. 01-DPAR-2024_Submission of Vet Pharma Product Dossiers in CTD Format | none published | Guidance | Unclassified | Tier 1 · Regulator-published |
| DEA-UG-2023-24522908 | 05 May 2023 | UG | Circular on importation and distribution of Hypodermic Syringes and Needles | none published | Guidance | Unclassified | Tier 1 · Regulator-published |
| DEA-UG-2023-96986397 | 17 Feb 2023 | UG | Signposts for drug outlets | none published | Guidance | Unclassified | Tier 1 · Regulator-published |
| DEA-UG-2021-19688059 | 07 Oct 2021 | UG | Labelling requirements for surgical sutures | none published | Guidance | Unclassified | Tier 1 · Regulator-published |
| DEA-UG-2021-60049757 | 28 Jun 2021 | UG | National Drug Authority statement on conduct of Clinical Trials during the COVID-19 lockdown | none published | Guidance | Unclassified | Tier 1 · Regulator-published |
| DEA-UG-2020-58346661 | 23 Dec 2020 | UG | Emergency use of Remdesivir in the context of the Covid-19 Pandemic | none published | Guidance | Unclassified | Tier 1 · Regulator-published |
| DEA-UG-2020-24052569 | 04 Nov 2020 | UG | Pharmacovigilance requirements for Remdesivir products under emergency imp | none published | Guidance | Unclassified | Tier 1 · Regulator-published |
| DEA-UG-2020-55852107 | 19 Oct 2020 | UG | Requirement for a Pharmacovigilance system for licensed persons in Uganda | none published | Guidance | Unclassified | Tier 1 · Regulator-published |
| DEA-UG-2020-86995705 | 23 Sept 2020 | UG | Provisions for emergency importation of Remdesivir in the context of the COVID-19 Pandemic | none published | Guidance | Unclassified | Tier 1 · Regulator-published |
| DEA-UG-2020-63618631 | 27 Mar 2020 | UG | Circular on Importation, Exportation & sale of Chloroquine & Hydroxychloroquine | none published | Guidance | Unclassified | Tier 1 · Regulator-published |
| DEA-UG-2020-12969129 | 26 Mar 2020 | UG | Caution against stockpiling and irrational use of medicine | none published | Guidance | Unclassified | Tier 1 · Regulator-published |
| DEA-UG-2019-54174102 | 18 Dec 2019 | UG | Communication circular on Clinical Trial new format for CT certificates | none published | Guidance | Unclassified | Tier 1 · Regulator-published |
| DEA-UG-2019-91714961 | 30 Jan 2019 | UG | Clarification on Hydrochlorothiazide | none published | Guidance | Unclassified | Tier 1 · Regulator-published |
| DEA-UG-2018-95689534 | 14 Dec 2018 | UG | Disabling and potentially permanent side effects associated with quinolone and fluoroquinolone antibiotics | none published | Safety communication | Unclassified | Tier 1 · Regulator-published |
| DEA-UG-2018-79023705 | 31 Aug 2018 | UG | Risk of crystalization of Mannitol 20% iv solution | none published | Safety communication | Unclassified | Tier 1 · Regulator-published |
| DEA-UG-2018-44654198 | Aug 2018 | UG | Increased risk of non-melanoma skin cancer associated with HCTZ | none published | Safety communication | Unclassified | Tier 1 · Regulator-published |
| DEA-UG-2018-57610380 | 23 May 2018 | UG | Gentamycin Injection | none published | Safety communication | Unclassified | Tier 1 · Regulator-published |
| DEA-UG-2018-20732652 | 26 Mar 2018 | UG | Risk of drug interactions and side effects due to use of herbal remedies – Anticancer Treatment | none published | Safety communication | Unclassified | Tier 1 · Regulator-published |
| DEA-UG-2018-83450762 | 27 Feb 2018 | UG | Certification of premises used to supply restricted drugs within institutions conducting clinical trials | none published | Guidance | Unclassified | Tier 1 · Regulator-published |
| DEA-UG-2018-54780957 | 15 Feb 2018 | UG | Risk of hypersensitivity reaction in infants and children following administration of Nevirapine | none published | Safety communication | Unclassified | Tier 1 · Regulator-published |
| DEA-UG-2017-41564009 | 11 Dec 2017 | UG | Increased risk of otoxicity following concomitant administration of Gentamicin and Furosemide | none published | Safety communication | Unclassified | Tier 1 · Regulator-published |
| DEA-UG-2022-30096701 | 01 Feb 2022 (uploaded) | UG | Implementation of the National Drug Policy and Authority (fees) Regulations 2022 | none published | Guidance | Unclassified | Tier 1 · Regulator-published |
Published by NDA but not an action against a product: draft regulations, import requirements, and safety signals about an active substance or a class of medicines rather than a particular pack. They are held to the same standard as everything else here — the source is archived, the verification tier is shown — and they are kept off the register because a batch search cannot answer a question about a whole drug class.
No action by another authority has been linked to this market.
Actions by other authorities that name this market on the notice, or that belong to a cross-border event this market also appears in. An absence here is an absence of recorded links, not a statement that no such product is on this market.